US OptionsDetailed Quotes
EYPT250117C15000
- 0.05
- -0.05-50.00%
15min DelayClose Jan 10 16:00 ET
0.05High0.05Low
0.05Open0.10Pre Close1 Volume419 Open Interest15.00Strike Price5.00Turnover241.24%IV80.46%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0497Delta0.0380Gamma166.80Leverage Ratio-0.0192Theta0.0001Rho8.30Eff Leverage0.0012Vega
EyePoint Pharmaceuticals Stock Discussion
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.
Positive
Positive interim DME trial data showing significant BCVA improvement of +8.9 letters
Successful completion of $161M equity financing
Extended cash runway into 2027
Initiation of Phase 3 LUGANO trial in wet AMD
Opening of new 40,000 sq ft cGMP manufacturing facility
Negative
Revenue declined 31% YoY to $10.5M from $15.2M
Net loss increased to $29.4M from $12.6M YoY
Operating expenses increased to $43.3M from $29.6M YoY
Cash position decreased to...
EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering
📊⚡️📊
Benzinga· 2 mins ago
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(7.8%)
NEWS
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Larger Image: tradingview.com...
$EyePoint Pharmaceuticals (EYPT.US)$
No comment yet